Zeria Pharmaceutical Co., Ltd.

4559.T
Drug Manufacturers - Specialty & Generic
2026/01/16 Updated
Market Cap: $583.3M (¥92.4B)
Stock Price: $13.23 (¥2,097)
Exchange Rate: 1 USD = ¥158.48

Stock Price Chart

2026/01/16 Updated
16.47
PER (Price Earnings Ratio)
vs Industry Avg: +6.9
1.01
PBR (Price to Book Ratio)
vs Industry Avg: -0.3
2.29%
Dividend Yield
vs Industry Avg: -0.66%

Price Trend

2026/01/16 Updated
Short-term
5-Day MA
-0.29%
Near-term
25-Day MA
+1.38%
Mid-term
75-Day MA
+3.87%
Long-term
200-Day MA
+1.24%

Price & Trading Details

2026/01/16 Updated

PRICE

Previous Close ¥2,088
Open ¥2,087
High ¥2,110
Low ¥2,087
Close ¥2,097

TRADING

Volume 59,800
Average Volume 97,296
Turnover ¥1億
Min. Purchase ¥209,700

Analyst Recommendations 1 analysts

Updated 2026/01/11
Strong Buy
0
Buy
1
1
Hold
0
Sell
0
Strong Sell
0
Target Price (Mean)
¥2,400
None
¥2,400
High
¥2,400
Median
¥2,400
Low
+14% vs Current Price
This information is based on market data from third-party data providers and is for reference only. Investment decisions are your own responsibility.

Shareholder Composition

Updated 2026/01/11
29.2%
Insider Holdings
20.5%
Institutional
50.3%
Public Float
71
Institutional Holders
Insider Holdings 29.2%
Institutional 20.5%
Public Float 50.3%

Dividend History 4Years Growth

Updated 2026/01/11
2.26%
Dividend Yield
¥48
Annual Dividend
+6.7%
YoY Growth
21.3%
Payout Ratio
Year Dividend Change
2025 ¥48 +6.7%
2024 ¥45 +2.3%
2023 ¥44 +22.2%
2022 ¥36 +5.9%
2021 ¥34 -

Financial Performance

2026/01/11 Updated

Revenue & Profit

Margins

Cash Flow

Financial Health

2022 2023 2024 2025
Income Statement
Revenue ¥59,533M ¥68,383M ¥75,725M ¥87,311M
Gross Profit ¥42,148M ¥49,489M ¥55,501M ¥63,960M
Operating Income ¥6,366M ¥9,015M ¥9,622M ¥12,198M
Pretax Income ¥6,037M ¥7,610M ¥9,966M ¥13,071M
Net Income ¥3,961M ¥6,196M ¥7,731M ¥9,936M
EPS ¥87.76 ¥140.26 ¥175.39 ¥225.42
Operating Margin 10.69% 13.18% 12.71% 13.97%
Balance Sheet
Total Assets ¥124,282M ¥135,035M ¥150,534M ¥159,172M
Total Equity ¥54,895M ¥65,450M ¥79,623M ¥89,540M
Total Liabilities ¥69,388M ¥69,585M ¥70,911M ¥69,632M
Cash ¥11,704M ¥16,219M ¥20,324M ¥23,593M
Interest-bearing Debt ¥52,229M ¥49,432M ¥46,228M ¥41,164M
Equity Ratio 44.17% 48.47% 52.89% 56.25%
D/E Ratio 0.95 0.76 0.58 0.46
Cash Flow
Operating CF ¥8,951M ¥13,157M ¥12,184M ¥12,922M
Investing CF -¥2,893M -¥2,575M -¥3,952M -¥1,051M
Financing CF -¥4,841M -¥7,415M -¥8,124M -¥7,757M
Free CF ¥7,530M ¥10,500M ¥8,285M ¥10,188M
Efficiency
ROE 7.22% 9.47% 9.71% 11.10%
ROA 3.19% 4.59% 5.14% 6.24%

Latest IR Information

  • No IR information found for this company.

    Searched stock code: 4559

Company Information

English Name Zeria Pharmaceutical Co., Ltd.
Japanese Name ゼリア新薬工業(株)
Stock Code 4559.T (JPX)
Sector / Industry Healthcare / Drug Manufacturers - Specialty & Generic
Employees 1,746

About

Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural and industrial chemicals, and reagents in Japan and internationally. The company operates through Ethical Pharmaceuticals Business and Consumer Healthcare Business segments. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company also offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia, and iron deficiency anemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; and non-steroidal anti-inflammatory ophthalmic solutions. In addition, it provides consumer healthcare products, such as nutritional health drugs, remedies for gastrointestinal diseases, western herbal medicines, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and food for specified health uses. Further, the company engages in insurance agency and real estate business. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was incorporated in 1955 and is headquartered in Tokyo, Japan.

Data provided by Yahoo Finance